Daunorubicin

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DRUG-DAUNORUBICIN`
Type	Drug
Aliases	CerubidineVyxeos (liposomal daunorubicin + cytarabine)Даунорубіцин
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-ELN-AML-2022` `SRC-NCCN-AML-2025`

Drug Facts

Class	Anthracycline (topoisomerase II inhibitor + DNA intercalator)
Mechanism	Intercalates into DNA, inhibits topoisomerase II, generates free radicals. Cumulative cardiotoxicity dose-dependent. Backbone of AML 7+3 induction.
Typical dosing	AML 7+3 induction: 60 mg/m² IV days 1-3 (standard); 90 mg/m² days 1-3 (intensified, ECOG-ALL trial — younger fit patients <60). Vyxeos (liposomal): 44 mg/m² daunorubicin + 100 mg/m² cytarabine days 1, 3, 5 for tAML / AML-MRC.
Ukraine registered	True
NSZU reimbursed	True
Ukraine last verified	2026-04-27

Warnings

Cardiotoxicity (cumulative; risk rises sharply >550 mg/m²)
Severe myelosuppression
Vesicant — extravasation causes severe tissue necrosis

Notes

Backbone of 7+3 (cytarabine 100-200 mg/m² CIVI d1-7 + daunorubicin 60-90 mg/m² d1-3). Idarubicin 12 mg/m² is an interchangeable alternative (especially in some European protocols). Baseline LVEF + lifetime anthracycline dose tracking mandatory.

Used By

Regimens

REG-AAML1031-PEDIATRIC - AAML1031-style induction (Cytarabine + Daunorubicin + Etoposide, pediatric AML 1L)
REG-AML-7-3 - 7+3 Induction (cytarabine + daunorubicin/idarubicin) ± midostaurin
REG-AML-7-3-GO - 7+3 + fractionated gemtuzumab ozogamicin (CD33+ AML, 1L; ALFA-0701)
REG-QUIZARTINIB-7-3 - 7+3 + quizartinib induction + maintenance for FLT3-ITD+ AML 1L